April 8, 2019 09:09 AM EDT
Pharma

Cel­gene, Ac­celeron sub­mit FDA ap­pli­ca­tion for billed block­buster lus­pa­ter­cept — will they get pri­or­i­ty re­view?

Natalie Grover

Reporter

Cel­gene and their part­ners at Ac­celeron are count­ing on their red blood cell boost­ing drug to win a speedy re­view as they sub­mit­ted a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times